Etoricoxib is a Small Molecule owned by Merck & Co, and is involved in 44 clinical trials, of which 43 were completed, and 1 is ongoing.

Etoricoxib is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.

The revenue for Etoricoxib is expected to reach a total of $2.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Etoricoxib NPV Report.

Etoricoxib is currently owned by Merck & Co. Organon is the other company associated in development or marketing of Etoricoxib.

Etoricoxib Overview

Etoricoxib (Arcoxia, Auxib, Turox, Exxiv, Hetori, Exinef, Acoxxel) is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) acts as analgesic agent. It is formulated as tablets and film coated tablets for oral route of administration. Etoricoxib is indicated for the treatment of symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis, treatment of moderate postoperative acute to severe pain associated with dental surgery, relief of chronic and acute pain and moderate acute postoperative pain associated with severe abdominal gynecological surgery.

Organon Overview

Organon is a healthcare company. The company discovers and develops biosimilars and medicines. It provides medicines and solutions for various conditions including respiratory, cardiovascular, dermatology, non-opioid pain, women’s health and others. The company’s products include mometasone furoate inhalation powder, follitropin beta injection, alendronate sodium, acetate injection, chorionic gonadotropin and others. It conducts patient assistance and Organon access program, which provide free medicines to individuals. Organon markets its products through a network of distribution channels in domestic and overseas markets. It works in collaboration with pharmaceutical and biopharmaceutical companies to commercialize its products. Organon is headquartered in Jersey City, New Jersey, the US.

The company reported revenues of (US Dollars) US$6,304 million for the fiscal year ended December 2021 (FY2021), a decrease of 3.5% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 42.1% in FY2020. In FY2021, the company recorded a net margin of 21.4%, compared to a net margin of 33.1% in FY2020. The company reported revenues of US$1,537 million for the third quarter ended September 2022, a decrease of 3% over the previous quarter.

Quick View – Etoricoxib

Report Segments
  • Innovator (NME)
Drug Name
  • Etoricoxib
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Immunology
  • Musculoskeletal Disorders
  • Women’s Health
Key Companies
  • Sponsor Company: Merck & Co
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.